Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02812160 · ClinicalTrials.gov registry record · NA

Spatz Adjustable Balloon for Obesity (SABO)

A NA study of Obesity, sponsored by Spatz FGIA.

Completed
Registry status
NA
Development phase
288
Enrollment target
7
Study locations

NCT02812160: Completed NA study of Obesity, sponsored by Spatz FGIA.

NCT02812160 is a NA study of Obesity that has completed, run by Spatz FGIA. The registered enrollment target is 288 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (65% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02812160, a NA study of Obesity, has completed, sponsored by Spatz FGIA.

COMPLETED
Registry status
NA
Development phase
288 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to determine whether the Spatz3 Adjustable balloon, a non-surgical device, is effective in the treatment of obesity.

Primary Outcome

The mean %TBL in the Spatz3 group should exceed the %TBL control group by 4.5%.

Conditions Studied

Interventions

  • DEVICE Spatz3 Adjustable Balloon

Study Locations (7)

Illinois

  • University of Chicago - Chicago

Louisiana

  • Surgical Specialists of Louisiana - Metairie

Maryland

  • Endoscopic MicroSurgery Associates - Towson

Massachusetts

  • Brigham and Womans Hospital - Boston

Minnesota

  • Mayo Clinic - Rochester

New York

  • NY Manhattan VA Hospital - New York

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 288 participants
Start Date 2016-09-12
Est. Completion 2019-01
Phase NA
Spatz FGIA

2 total trials

What the finished NCT02812160 record still lists

NCT02812160 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Spatz3 Adjustable Balloon is the first listed.

NCT02812160 lists 7 locations in 7 states (Illinois, Louisiana, Maryland).

Frequently Asked Questions

What is clinical trial NCT02812160 about?

NCT02812160 is a clinical study titled "Spatz Adjustable Balloon for Obesity (SABO)". The purpose of this study is to determine whether the Spatz3 Adjustable balloon, a non-surgical device, is effective in the treatment of obesity.

What is the current status of trial NCT02812160?

This trial is currently completed. It is a NA study. The enrollment target is 288 participants. The study started on 2016-09-12. Estimated completion is 2019-01.

What conditions does trial NCT02812160 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT02812160?

The interventions under investigation include: Spatz3 Adjustable Balloon (DEVICE).

Who is sponsoring clinical trial NCT02812160?

This trial is sponsored by Spatz FGIA, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02812160 being conducted?

This trial has 7 study locations across Illinois, Louisiana, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02812160's enrollment target sits among peer trials

288 234th of 1053 higher than 819 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02098265 · 288 participants · NA

    A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device

  • NCT03741777 · 288 participants · NA

    Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume

  • NCT03937635 · 288 participants · Phase 3

    Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  • NCT04621877 · 288 participants · NA

    Lay-Delivered Behavioral Activation in Senior Centers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02812160, the US trial registry maintained by the National Library of Medicine. NCT02812160 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.